Karine Tawagi, University of Illinois Chicago, shared a post on X:
“Prostate CA panel at Uromigos day 2 on:
radioligands:
-clinically meaningful SUV threshold?
-pre-chemo Lu-617 approvals in real world?
-issue with cytopenias -individualized dosimetry? PET q2cycles?
The future T cell engagers (ph1 Tarlatamab DLL3 in NEPC), beware CRS.”
Source: Karine Tawagi/X
